More Stories

Informist, Thursday, Apr. 30, 2026

MUMBAI – Shares of pharmaceutical companies are expected to trade within a range, with some stock-specific movement likely from companies slated to release earnings next week. Some analysts said pharmaceutical stocks are a good defensive buying opportunity in a market jolted by a fall in stocks that are sensitive to the surge in crude oil prices. Investors will also be on the lookout for plans for new inorganic growth from companies after news of Sun Pharmaceutical Industries' record acquisition of Organon.

"We still continue to maintain a buy-on-dips trading approach in this (pharmaceutical) space," Vipin Kumaar, senior technical and derivatives analyst at Globe Capital Markets, said. The Nifty Pharma index is trading on the verge of a bullish breakout from the past 18 months, the analyst said. He said a decisive close above the 23600 level will lead it towards 24000 levels in the near-term and towards 25500 and higher levels in the medium-term. Next week, the index will face resistance at 24000 points and find support at 22500 points.

This week, the Nifty Pharma index closed 3.1% higher compared with 0.4% rise in the Nifty 50. Sun Pharmaceutical Industries rose 12% during the week. Glenmark Pharmaceuticals and Divi's Laboratories reported gains of 4% and 3%, respectively. Meanwhile, Zydus Lifesciences dropped almost 4%, Piramal Pharma ended over 2% lower, and Aurobindo Pharma closed down nearly 2%.

Piramal Pharma and Syngene International reported their earnings during the week. Syngene reported a near 15% on year decline in its net profit to INR 1.48 billion in the March quarter. Its revenue growth almost stalled, rising just 1.2% to INR 9.60 billion. Piramal Pharma reported a consolidated loss of INR 88.2 million for the March quarter compared to a net profit of INR 1.54 billion a year ago. Its revenue grew marginally on year to INR 27.52 billion. The company's contract development and manufacturing business was impacted by de-stocking, ICICI Direct said. Improving biopharmaceutical funding is translating into stronger requests for proposals and a pickup in order inflows for the CDMO segment, the brokerage said.

Lupin will announce its results on May 7. The company is likely to report a sharp rise in revenue and the bottom line for the March quarter, driven by strong growth in its US business. Some brokerages project the pharmaceutical company will grow the fastest among its peers organically. The company's consolidated net profit for the March quarter is expected to surge over 56% on-year to INR 12.06 billion, while its revenue is expected to rise 22.8% to INR 69.59 billion for the reporting quarter.

TOP HEADLINES

* Acutaas Chemicals Jan-Mar consol PAT doubles on year to INR 1.32 billion
* US FDA issues 5 observations after investigating Biocon's biosimilars site
* Syngene Intl Jan-Mar net profit falls 15% YoY to INR 1.48 billion
* Granules India Jan-Mar consol PAT surges nearly 33% YoY to INR 2.02 billion
* Dr Reddy's gets Health Canada approval for generic Semaglutide injection
* Piramal Pharma posts INR 88.2 mln loss in Jan-Mar, fails to beat Street view
* Organon acquisition to boost Sun Pharma EPS, sales in FY28, brokerages say
* Wockhardt board to consider FY26 results, fund-raising proposals Monday
* Sun Pharma to focus on 'eliminating' debt needed to buy US co Organon
* Analyst Concall: Sun Pharma to foray into biosimilar market via Organon buy
* SC to examine if plea to revoke patent can be filed even after its expiry
* Analyst Concall: Sun Pharma to foray into biosimilar mkt via Organon buy
* CORRECTS: Sun Pharma to buy US co Organon for $11.75 bln to boost global ops
* Cohance Lifesciences appoints Umang Vohra as chairman, group CEO
* Sun Pharma to acquire US-based Organon for $11.75 bln to boost global ops
* Zydus Life gets DCGI nod to initiate phase-III trials of Zintrodiazine
* Alkem Labs says tax dept has disputed co's tax amount of INR 3.33 bln
* Alkem Lab CEO Vikas Gupta resigns, to leave post on Jun 30

Following are the resistance and support levels for key pharmaceutical stocks for next week as per calculations based on their prices on the National Stock Exchange:

End

Reported by Eshitva Prakash

Edited by Saji George Titus

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2026. All rights reserved.